The aim of this study was to identify candidate single-nucleotide polymorphisms (SNPs) that may play a role in the susceptibility to glioma, to elucidate their potential mechanisms, and to generate SNP-to-gene-to-pathway hypotheses.
Glioma, a fatal neurological cancer associated with considerable morbidity, represents up 80% of all malignant brain tumors [1] . Although glioma is a complex and heterogeneous disease and its etiology has not been determined, case-controlled and family studies have established a genetic component to disease susceptibility [2] . Previous genome-wide association studies (GWASs) have uncovered glioma-associated single-nucleotide polymorphisms (SNPs) within genes such as coiled-coil domain containing 26 (CCDC26), regulator of telomere elongation helicase 1 (RTEL1), pleckstrin homology-like domain, family B, member 1 (PHLDB1), tumor protein p53 (TP53), cyclindependent kinase inhibitor 2A/B (CDKN2A/B), epidermal growth factor receptor (EGFR), and telomerase reverse transcriptase (TERT) [2, 3] .
GWASs offer a powerful means to search for genes that confer susceptibility to complex diseases [4] . As a result of increasing numbers of GWASs are being reported, and have led to the discovery and validation of novel disease genes [5] . Although large-scale GWASs have been carried out on complex diseases including glioma, many genetic components that contribute to variations in glioma remain unexplained.
Reports to date suggest that individual genes and genetic variants interact with each other to confer small risk contributions to glioma susceptibility. Although a number of genetic signals have been examined at the single-marker level in glioma GWAS studies, the biological mechanisms identified remain controversial [6] . One of the key challenges in interpreting GWAS data is to identify glioma-associated SNPs and provide evidence for the hypothetical mechanisms that could be responsible for observed traits [7] [8] [9] . Thus, we hypothesized that development of novel methods to study existing GWAS datasets would provide additional insight and identify new candidate genes. Identify candidate Causal SNPs and Pathways (ICSNPathway) analysis was developed to identify SNPs candidate and their corresponding candidate pathways using GWAS data together with linkage disequilibrium (LD) analysis, functional SNP annotation, and pathway-based analysis (PBA) [10] .
We applied ICSNPathway analysis to a glioma GWAS dataset to identify candidate SNPs and mechanisms of glioma susceptibility, and to generate SNP-to-gene-to-pathway hypotheses.
Materials and methods
Study population. We used a publicly available glioma GWAS dataset from the National Center for Biotechnology Information (NCBI) dbGap (http://www.ncbi.nlm.nih.gov/ projects/gap/cgi-bin/study.cgi?study_id=phs000652.v1.p1), which included the genotypes of 524,589 SNPs obtained from the Human610_Quadv1_B, Human660W-Quad_v1_A, and HumanHap550v3.0 platforms. The dataset comprised 1,856 glioma patients and 4,955 controls of European descent (studies with more than 80% European-ancestry subjects) from 14 cohort studies belonging to the Cohort Consortium, 3 case-control studies, and 1 population-based case-only study [3] . Cases were newly diagnosed glioma [ICDO-3 codes 9380-9480 or equivalent], and controls were healthy individuals. The dataset was filtered to remove SNPs showing significant (p < 0.001) Hardy-Weinberg violation, and a call rate cut-off value of <98% was used to reduce the impact of genotyping errors. In all, 509,345 SNPs passed the quality control filters.
Identification of candidate causal SNPs and pathways. ICSNPathway analysis was carried out in 2 stages [10] . The first stage involved the pre-selection of candidate causal SNPs by linkage disequilibrium (LD) analysis and functional SNP annotation based on the most significant SNPs. The second stage involved annotating the biological mechanisms underlying pre-selected candidate causal SNPs using the PBA algorithm, i-GSEA (improved gene-set enrichment analysis). A full list of glioma GWAS SNP p-values was entered into the ICSNPathway analysis. One concept utilized in the ICSNPathway analysis is LD analysis, which searches the GWAS dataset for the most significant SNPs in LD to identify additional candidate causal SNPs based on an extended dataset, including Hapmap data [11] . The other method involves the use of functional SNPs. ICSNPathway analysis pre-selects candidate causal SNPs based on functional SNPs, which are important factors in the underlying genetics of human health. Functional SNPs are defined as SNPs that alter protein or gene expression or the role of a protein in the context of a pathway. They include deleterious and non-deleterious non-synonymous SNPs, SNPs that cause the gain or loss of a stop codon, those resulting in a frameshift, and those located in essential splice sites or regulatory regions. The ICSNPathway server applies the i-GSEA PBA algorithm to the full list of GWAS SNP p-values to detect the pathways associated with individual traits. Briefly, the process is as follows. (i) Each SNP is mapped to its nearest gene according to their respective loci in the Ensembl 61 database (http://www.wnsembl.org/biomart/martview), and the maximum SNP t = −log(p-value) values mapped to genes are assigned to represent those genes. Then, all genes are ranked by decreasing representative t values. (ii) For each pathway S, the enrichment score (ES, i.e., a Kolmogorov-Smirnov-like running-sum statistic with weight [a]) is calculated, which measures the tendency for genes of a pathway to be located at the top of the ranked gene list. (iii) The ES is then converted to a significant proportion-based ES (SPES) by multiplying the ES by m 1 /m 2 , where m 1 is the proportion of significant genes for the pathway S (defined as genes mapped with at least one SHLP among the top 5% of the most significant SNPs in the GWAS), and m 2 is the proportion of significant genes for all genes in the GWAS. (iv) SNP label permutation and normalization are employed to generate the distribution of SPESs and to correct for gene variation (bias caused by different genes with different numbers of mapped SNPs) and pathway variation (bias due to different pathways with different numbers of genes). (v) Based on the distribution of SPES values generated by the permutation, a nominal p-value is calculated, and a false discovery rate (FDR) is computed for multiple testing correction.
The phrase "the most significant SNPs" refers to SNPs with a p-value below a certain threshold, which can be specified from the GWAS SNP p-values. The ICSNPathway was used to analyze significant pathways from the original GWAS data when we chose the p-value threshold (<1 × 10 -3 ) used in the study. two parameters were set for the analysis. The first was "within gene, " meaning that only p-values of SNPs located within genes were used in the PBA algorithm. The second was an FDR cut-off (0.05) for multiple testing corrections. Control of the FDR is preferred for large-scale testing. Defined as the expected proportion of false-positives among all significant tests, it allows researchers to identify a set of "candidate positives, " a high proportion of which are likely to be true-positives. The FDR, a permutation-based approach for multiple comparisons, was used to identify statistically significant genes. There were no specific criteria used to select the number of genes; we used a cut-off range of a minimum of 5 and maximum of 100 to avoid very narrow or very broad functional categories. We discarded pathways that contained over 100 genes to avoid stochastic bias and the inclusion of a general biological process. Out of the several options available for pathway annotation, we selected four pathway databases: the Kyoto Encyclopedia of Genes and Genomes (KEGG) [12] , BioCarta, gene ontology (GO) biological process [13] , and GO molecular function. This ensured comprehensive coverage of pathways and high-quality information for well-defined pathways.
SNAP was developed to identify and annotate nearby SNPs in LD (proxies) by Hapmap (http://www.broadinstitute.org/ mpg/snap/). In this study, we used SNAP to: (i) find proxy SNPs, (ii) determine whether SNP proxies were present in genes, (iii) resolve whether associations from multiple SNPs represented similar associations, (iv) plot regional views of associations or LD structures, and (v) retrieve annotations for SNPs [14] .
Results
Candidate SNPs and pathways identified from glioma GWASs. Utilizing the 509,345 GWAS SNP p-values as the input and the most significant SNPs (p < 1 × 10
), ICSNPathway analysis identified 6 candidate SNPs, 5 genes, and 9 pathways (tables 1, 2, and 3; Figure 1 ). The 6 candidate SNPs were rs667128 (−log 10 were not in LD with any other SNP. SNP rs4644, which was in LD with rs8007614 (r 2 = 0.853), was not represented in the original GWAS dataset. Similarly, rs4652 was not represented in the original GWAS, and was in LD with rs8007614 (r 2 = 0.96). The biological mechanisms suggest that the candidate SNPs may alter the role of their corresponding gene or protein in the context of pathway-associated traits. The 6 candidate SNPs were associated with 9 candidate pathways, having roles in 5 hypothetical biological mechanisms. The hypothetical mechanisms, beginning with the strongest, can be summarized as follows: (i) rs667128 (regulatory region) alters the role of TAS2R8 in taste receptor activity and taste transduction pathways (p < 0.001, FDR < 0.001; p = 0.001, FDR = 0.012), (ii) rs619381(nonsynonymous coding (deleterious)) modulates the effect of TAS2R7 on taste receptor activity and taste trans- Using a pathway-based approach, we next investigated which genes played roles in the identified pathways and found a distinct clustering of genes involved in the candidate glioma-causal pathways. The most significant pathway was the taste receptor activity pathway, specifically involving TAS2R7, TAS2R14, TAS2R9, TAS2R13, TAS1R2, TAS1R1, and TAS2R16 (p < 0.05). The second most significant pathway was that regulating cell adhesion, which involved cyclin-dependent kinase inhibitor 2A (CDKN2A), delta-like protein 1 (DLL1), cadherin 13 (CDH13), a disintegrin and metalloproteinase domain-containing protein (ADAM10), transglutaminase 2 (TGM2), GtP binding protein 4 (GTPBP4), kininogen 1 (KNG1), azurocidin 1 (AZU1), arachidonate 12-lipoxygenase (ALOX12), neurofibromatosis type 2 (NF2), Rho GDP dissociation inhibitor (GDI) beta (ARHGDIB), tuberous sclerosis 1 (TSC1), endomucin (EMCN), phosphatase and tensin homolog (PTEN), transforming growth factor, beta-induced (TGFBI), neurofibromatosis type I (NF1), cluster of differentiation 47 (CD47), cyclin-dependent kinase 6 (CDK6), beta-1,4-N-acetyl-galactosaminyl transferase 2 (B4GALNT2), Table 2 . Functional and association study of genes identified by GWAS pathway analysis
Gene Function

TAS2R8
This gene product belongs to the family of candidate taste receptors, which are members of the G-protein-coupled receptor superfamily. These proteins are specifically expressed in the taste receptor cells of the tongue and palate epithelia. They are organized in the genome in clusters and are genetically linked to loci that influence bitterness perception in mice and humans. In functional expression studies, they respond to bitter tastants. This gene maps to the taste receptor gene cluster on chromosome 12p13.
TAS2R7
Gustducin-coupled receptor implicated in the perception of bitter compounds in the oral cavity and the gastrointestinal tract. Signals through phospholipase C, beta 2 (PLCB2) and the calcium-regulated transient receptor potential cation channel, subfamily m, member 5 (tRPm5).
DLL1
DLL1 is a human homolog of the Notch Delta ligand and is a member of the delta/serrate/jagged family. It plays a role in mediating cell fate decisions during hematopoiesis. It may play a role in cell-to-cell communication. It acts as a ligand for Notch receptors, and blocks the differentiation of progenitor cells into the B-cell lineage while promoting the emergence of a population of cells with t-cell/NK-cell precursor characteristics.
LBP
The protein encoded by this gene is involved in the acute-phase immunologic response to gram-negative bacterial infections. Gram-negative bacteria contain a glycolipid, lipopolysaccharide (LPS), on their outer cell wall. together with bactericidal permeability-increasing protein (BPI), the encoded protein binds LPS and interacts with the CD14 receptor, probably playing a role in regulating LPS-dependent monocyte responses. Studies in mice suggest that the encoded protein is necessary for the rapid acute-phase response to LPS but not for the clearance of LPS from circulation. This protein is part of a family of structurally and functionally related proteins, including BPI, plasma cholesteryl ester transfer protein (CEtP), and phospholipid transfer protein (PLtP). It binds to the lipid A moiety of bacterial lipopolysaccharides (LPS), a glycolipid present in the outer membrane of all Gram-negative bacteria, and acts as an affinity enhancer for CD14, facilitating its association with LPS.
LGALS3
This gene encodes a member of the galectin family of carbohydrate-binding proteins. members of this protein family have an affinity for betagalactosides. The encoded protein is characterized by an N-terminal proline-rich tandem repeat domain and a single C-terminal carbohydrate recognition domain. This protein can self-associate through the N-terminal domain, allowing it to bind to multivalent saccharide ligands. It localizes to the extracellular matrix, the cytoplasm and the nucleus and plays roles in numerous cellular functions including apoptosis, innate immunity, cell adhesion and t-cell regulation. Alternate splicing results in multiple transcript variants.
signal-regulatory protein gamma (SIRPG), RAS p21 protein activator (GtPase activating protein) 1 (RASA1), Rho GDP dissociation inhibitor (GDI) gamma (ARHGDIG), Rho family GtPase 1 (RND1), interleukin 12B (natural killer cell stimulatory factor 2, cytotoxic lymphocyte maturation factor 2, p40) (IL12B), activin A receptor type II-like 1 (ACVRL1), interleukin 18 (interferon-gamma-inducing factor) (IL18), and chemokine (C-X3-C motif) ligand 1 (CX3CL1) (p < 0.05). The third pathway was taste transduction. Previous study revealed that sweet taste receptors might play important roles in the tumorigenesis in the nervous system [15] . The fourth pathway was response to LPS. LPS induces nitric oxide (NO) in rat glioma C6 [16] , and the study suggested NO derived from inflammation may contribute to the progression of carcinogenesis [16] . The sixth pathway was acute inflammatory response. It is well known that inflammation plays important roles in the pathogenesis of brain tumor [17] . The seventh pathway was macrophage activation, which leads to change in the morphology and behavior of a macrophage resulting from exposure to a cytokine, chemokine, or cellular ligand, and plays a key role in the immune and inflammatory responses. The eighth pathway was segment specification, which assumes individual identities and is exemplified in insects by the actions of the products of the homeotic genes. The ninth pathway was immunoglobulin binding, which interacts selectively and non-covalently with an immunoglobulin. The pathways of segment specification and immunoglobulin binding are involved in the immune system. Glioma development and progression is dependent on evading the immune system by mediating immunosuppression and immune evasion. Lack of recruitment of naïve effector immune cells accounts for most of the immune suppression mediated by glioma cells [15] . Genes without a known immunological function are of particular interest because of their potential to lead to the identification of novel mechanisms for the susceptibility to glioma. This analysis suggests that the pathways and genes identified by PBA may contribute to patient susceptibility to glioma.
Discussion
Various cellular pathways involving complex molecular networks may play key roles in the development of glioma [18] . If a specific pathway was relevant to disease susceptibility, association signals would be expected to be overrepresented for SNPs in that pathway [4, [19] [20] [21] . Given the limited power of GWAS to detect single SNP associations, we adopted a pathway-based approach to take into account the biological interplay between genes and to provide insight into how multiple genes might contribute to the pathogenesis of glioma [22] [23] [24] .
In the present study, we used ICSNPathway analysis to identify 6 candidate SNPs, 5 genes, and 9 pathways, which provided 5 hypothetical biological mechanisms. The most significant SNP-to-gene-to-effect hypothesis was that of rs667128 altering the role of TAS2R8 in taste receptor activity and taste transduction pathways. This gene product is a candidate taste receptor belonging to the G-protein-coupled [25] . the second strongest mechanism was one wherein rs619381 modulates TAS2R7-mediated effects in pathways of taste receptor activity and taste transduction. TAS2R7 plays a role as a G (Gustducin)-coupled receptor and is implicated in the perception of bitter compounds in the oral cavity and gastrointestinal tract [26] . taste receptor cells in the taste buds transmit gustatory information to the nervous system. Glucose is an essential substrate for brain oxidative metabolism [27] . Brain glucosensors are specialized neurons, modulating their mean firing rate according to changes in glucose concentration [28] . Sweet taste receptors and G-protein-coupled receptor are proposed to be associated with brain glucose sensor [15] . Thus, taste-like signaling mechanisms in the brain might be involved in the central regulation of homeostatic processes.
A study showed increased expression of sweet taste receptors in C6 rat glioma, suggesting sweet taste receptors might play important role in the tumorigenesis in the mammalian nervous system [15] . The third mechanism identified in this analysis was the modulation of DLL1 by rs1033583 in the regulation of cell adhesion and segment specification. DLL1 acts as a ligand for Notch receptors and blocks the differentiation of progenitor cells into the B-cell lineage while promoting the emergence of a population of cells with t-cell/natural killercell precursor characteristics [29] . It plays a role in mediating cell fate decisions during hematopoiesis and might also play a role in cell-to-cell communication. DLL1 is overexpressed in glioma cell lines and primary human gliomas, and downregulation of DLL1 by RNA interference inhibits proliferation and induces apoptosis in multiple glioma cell lines [30] . The fourth mechanism was that rs2232580 affects the role of LBP in the response to lipopolysaccharide (LPS), positive regulation of interleukin-6 production, acute inflammatory response, and in macrophage activation. monocytes and neutrophils required for the innate immune response against LPS and lipoarabinomannan (LAm) express CD14 on their surfaces. LBP acts as an affinity enhancer by disaggregating and catalytically transferring LPS to CD14 [31] . In addition, the CD14-dependent LAm response is greatly facilitated by the addition of LBP [32] . LBP is involved in the acute-phase immunologic response to gram-negative bacterial infections. LPS induces nitric oxide (NO) in rat glioma C6, suggesting NO derived from inflammation may contribute to the progression of carcinogenesis [16] . Inflammatory responses may play a key role in the pathogenesis of brain tumor [17] . The fifth mechanism was that rs4644 and rs4652 regulate LGALS3, affecting immunoglobulin binding. This gene encodes a member of the galectin family of carbohydrate-binding proteins and plays roles in numerous cellular functions including apoptosis, innate immunity, cell adhesion, and t-cell regulation [33] . In the nucleus, LGALS3 acts as a pre-mRNA splicing factor, and is involved in acute inflammatory responses including neutrophil activation and adhesion, chemoattraction of monocytes and macrophages, opsonization of apoptotic neutrophils, and activation of mast cells [33] .
LGALS3 accelerates macrophage infiltration and angiogenesis in tumors [34] , and is known to be increasingly activated in microglia and macrophages as glioma progresses [35] . There is increasing evidence that the development of malignant disorders is related to complex pathways involving the immune system and inflammatory response [36, 37] . Our analysis, which identified 5 candidate genes that could contribute to glioma risk (TAS2R8, TAS2R7, DLL1, LBP, and LGALS3), uncovered promising glioma-associated genes and pathways related to the immune system and inflammatory responseAlthough additional studies are needed to confirm the association between glioma and these SNPs, genes, and pathways, pathway-based approaches play a complementary role in the identification of novel genes conferring disease susceptibility. Therefore, the results obtained in the present study may lead to the formulation of novel hypotheses for future investigation. It is well known that most causative genetic alterations in human gliomas involve in either activation of tyrosine kinase pathway or disruption of cell cycle arrest pathways, such as EGFR, PDGFR, p53, p16, p19, cyclin D [2, 3] . However, we did not identify those pathways using our approach. There are two possible explanations on the difference. First, the candidate genes have been identified by univariate analyses of individual SNPs, such as GWAS. GWAS focuses the SNPs with the highest statistical significance, and the genes identified by GWAS account for only a small portion of the heritability of diseases. testing of each SNP is not well suited for detecting multiple variants with small effects. However, glioma is caused by multiple genetic factors interacting with environmental factors and complex molecular network and pathways play key roles in the susceptibility of glioma. ICSNPathway is used to identify disease-related SNPs, genes, and pathways by interpreting the full list of GWAS SNPs, instead of the most significant SNPs, and searching a large pathway databases. ICSNPathway considers not only the strong association signal of most significant SNPs, but also the combined effect of modest SNPs, which ensures a comprehensive analysis, and play a complementary role in the identification of novel genes that confer disease susceptibility. Second, ICSNPathway is not intended to be used to predict true causal SNPs and pathways because of the limited understanding of genetic basis of complex diseases. The outputs of ICSNPathway indicate possible candidate SNPs and pathways. Thus, we cannot rule out the possibility that our results may be false negative. Our findings suggest that relationships exist between glioma and the genes and pathways identified, but it is needed to validate our approach to identify glioma-associated genes and pathways. ICSNPathway is a novel and validated approach to identify causative genes of human diseases. ICSNPathway approach has been successfully applied to identify causative genes of other diseases such as rheumatoid arthritis [10] .
In summary, we examined a glioma GWAS dataset to identify genetic associations with glioma at both the SNP and pathway levels. By applying ICSNPathway analysis to the glioma GWAS dataset, we identified 6 candidate SNPs, 5 genes (TAS2R8, TAS2R7, DLL1, LBP, and LGALS3), 9 pathways, and 5 biological mechanisms that may contribute to glioma susceptibility. However, further studies are needed to confirm and explore the genetic variations of the molecular pathways that might be associated with glioma.
